Hodgkin-limfóma: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• CD20 2
• CD19 11
• PD-1 9
• CD30 9
• PD-L1 2
• BCL-2 2
• STAT3 0
• CD47 1
• JAK 1
• MYC 2
• TP53 0
• ALK 0
• BTK 1
• CD22 0
• IL-6 0
• AKT 0
• CTLA-4 0
• mTOR 0
• PI3K 0
• PRMT5 1
• ABL1 0
• BCMA 0
• CD123 1
• CD38 0
• EZH2 0
• METTL3 0
• NOTCH1 0
• NRF2 0
• TIM-3 0
• AMPK 0
• AXL 0
• BDNF 1
• CCR5 0
• CDK4/6 0
• CXCR4 0
• FGFR 0
• FLT3 0
• GLP-1 0
• HDAC 0
• IL-15 1
• IL-17 0
• MET 0
• MMP-9 0
• NLRP3 0
• PARP 0
• PRAME 0
• SGLT2 0
• SIRT1 0
• TERT 0
• TIGIT 0
• TLR4 0
• TNF 0

7+ intézményből 7, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · R01

  Integrating AI and Deep Mutational Scanning to Predict the Cancer-Promoting Effect of Shelterin Mutations

  University of California Berkeley· Berkeley, Egyesült Államok· 2 197 943 USD awarded in fiscal year 2026· until 2029. aug.

• NIH NIAID · U01

  Leveraging JAK Inhibitors to Halt Autoimmune Attack Induced by Immune Checkpoint Inhibitors

  University of California Los Angeles· Los Angeles, Egyesült Államok· 1 183 663 USD awarded in fiscal year 2026· until 2031. júl.

• NIH NCI · R37

  Trajectories of Neurotoxicity Among Patients with Adolescent and Young Adult Hodgkin Lymphoma

  University of Rochester· Rochester, Egyesült Államok· 814 967 USD awarded in fiscal year 2026· until 2031. aug.

• NIH NCI · R50

  Bridging National and Local Trial Systems to Expand Adolescent/Young Adult Participation in NCTN and NCORP Networks

  Columbia University Health Sciences· New York, Egyesült Államok· 187 037 USD awarded in fiscal year 2026· until 2031. aug.

• NIH NCI · R50

  Radiation Oncology Integration and innovation: Enhancing Lymphoma Trial Design and Establishing a Particle Therapy Research Pathway

  Mayo Clinic Jacksonville· Jacksonville, Egyesült Államok· 163 320 USD awarded in fiscal year 2026· until 2031. aug.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  SMART-SMAPs: a new paradigm of cell-free cytotoxic immunotherapy for resistant CLL

  Universita Degli Studi di Siena· Siena, Olaszország· EU contribution 150 000 EUR· until 2028. márc.· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Investigating the Interplay of Natural Killer Cells and Microbiome in Non-Hodgkin's Lymphoma (LINK-M)

  Luxembourg Institute of Health· Strassen, Luxemburg· EU contribution 216 240 EUR· until 2028. aug.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Integrated Assessment of Indoor Radon and Hazardous Air Pollutants in Non-Hodgkin Lymphoma – a Case-Control Study in a Radon-Prone Area (AlphaLymph)

  Universidad de Santiago de Compostela· Santiago De Compostela, Spanyolország· EU contribution 242 593 EUR· until 2029. febr.· 2 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Studying the Microenvironment And Related Targets in Non-Hodgkin's Lymphoma (SMART-NHL)

  Fundacio de Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi I Sunyer· Barcelona, Spanyolország· EU contribution 181 153 EUR· until 2027. aug.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Development and characterization of a novel CAR T-cell therapy for NHL (CARLY)

  Fundacio Institut de Recerca Contra la Leucemia Josep Carreras· Badalona, Spanyolország· EU contribution 226 441 EUR· until 2027. jún.

10 of 85 running projects, newest first. Listed amounts together: 56,6 M USD + 11,1 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL

  NCT06806033· Hoffmann-La Roche· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 5
• Mendelian Randomization Analysis 6
• CRISPR-Cas Systems 1
• Gene Expression Profiling 14
• Whole Genome Sequencing 1
• Exome Sequencing 3
• Proteomics 5
• Metabolomics 1
• Flow Cytometry 9
• Immunohistochemistry 19
• Liquid Biopsy 1
• Circulating Tumor DNA 6
• Xenograft Model Antitumor Assays 20
• Positron-Emission Tomography 21
• Magnetic Resonance Imaging 18
• Machine Learning 11
• Deep Learning 3
• Cohort Studies 30
• Genome-Wide Association Study 7

• Decoding the Heterogeneity of Diffuse Large B-Cell Lymphomas: A Comprehensive Genetic, Transcriptomic, and Phenotypic Profiling of B-Cell Lymphoma Cell Lines.

  Hematol Oncol, 2026. szept.

• Targeted Transcriptomic Profiling Identifies Biomarkers and Molecular Features Associated With Immunotherapy Response in Classic Hodgkin Lymphoma.

  Mod Pathol, 2026. aug.

• Single-cell sequencing uncovers clonal dynamics profiles and therapeutic resistance biomarkers in relapsed and refractory peripheral T-cell lymphoma.

  Front Immunol, 2026. júl.

• Multidimensional Characterization of Tumor-Immune Architecture Reveals Clinically Relevant Classic Hodgkin Lymphoma Subtypes.

  Cancer Discov, 2026. máj.

• Disordered differentiation and cellular senescence in pediatric Hodgkin Reed-Sternberg cells.

  Blood Adv, 2026. ápr.

• E2F Accelerates the Proliferation of B-Cell Non-Hodgkin Lymphomas by Upregulating Cell-Cycle Genes.

  Curr Med Sci, 2026. ápr.

• Transcriptome sequencing of Hodgkin lymphoma Hodgkin and Reed-Sternberg cells reveals escape from NK cell recognition and an unfolded protein response.

  Blood Cancer J, 2026. ápr.

• Spatial transcriptomics unveils immune cellular ecosystems associated with patient survival in diffuse large B-cell lymphoma.

  Oncoimmunology, 2026. ápr.

• Identification of plasma exosome circRNA as potential novel biomarkers for DLBCL and circrna-miRNA-mRNA network analysis.

  Clin Exp Med, 2026. ápr.

• Machine learning based on clinical and gene expression data assists in survival prediction and treatment optimization for diffuse large B-Cell lymphoma patients.

  Ann Hematol, 2026. febr.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.